eIF2β, a subunit of translation‐initiation factor EIF2, is a potential therapeutic target for non‐small cell lung cancer
Open Access
- 6 April 2018
- journal article
- research article
- Published by Wiley in Cancer Science
- Vol. 109 (6) , 1843-1852
Abstract
To identify novel therapeutic targets for non‐small cell lung cancer (NSCLC), we conducted an integrative study in the following 3 stages: (i) identification of potential target gene(s) through shRNA functional screens in 2 independent NSCLC cell lines; (ii) validation of the clinical relevance of identified gene(s) using public databases; and (iii) investigation of therapeutic potential of targeting the identified gene(s) in vitro. A semi‐genome‐wide shRNA screen was performed in NCI‐H358 cells, and was integrated with data from our previous screen in NCI‐H460 cells. Among genes identified in shRNA screens, 24 were present in both NCI‐H358 and NCI‐H460 cells and were considered potential targets. Among the genes, we focused on eIF2β, which is a subunit of heterotrimeric G protein EIF2 and functions as a transcription initiation factor. The eIF2β protein is highly expressed in lung cancer cell lines compared with normal bronchial epithelial cells, and gene copy number analyses revealed that eIF2β is amplified in a subset of NSCLC cell lines. Gene expression analysis using The Cancer Genome Atlas (TCGA) dataset revealed that eIF2β expression is significantly upregulated in lung cancer tissues compared with corresponding normal lung tissues. Furthermore, high eIF2β expression was correlated with poor survival in patients with lung adenocarcinoma, as shown in other cohorts using publicly available online tools. RNAi‐mediated depletion of eIF2β suppresses growth of lung cancer cells independently of p53 mutation status, in part through G1 cell cycle arrest. Our data suggest that eIF2β is a therapeutic target for lung cancer.Keywords
Funding Information
- Japan Society for the Promotion of Science
- University of Texas Southwestern Medical Center (P50CA70907)
- Cancer Prevention and Research Institute of Texas (RP110708)
This publication has 23 references indexed in Scilit:
- Identification of proteasomal catalytic subunit PSMA6 as a therapeutic target for lung cancerCancer Science, 2017
- XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancerNature, 2016
- Crystal structure of eukaryotic translation initiation factor 2BNature, 2016
- Lung Cancer Statistics2015
- An Integrated Prognostic Classifier for Stage I Lung Adenocarcinoma Based on mRNA, microRNA, and DNA Methylation BiomarkersJournal of Thoracic Oncology, 2015
- The Global Burden of Cancer 2013JAMA Oncology, 2015
- Roles of the translation initiation factor eIF2α serine 51 phosphorylation in cancer formation and treatmentBiochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms, 2015
- Non-small-cell lung cancers: a heterogeneous set of diseasesNature Reviews Cancer, 2014
- Ran Is a Potential Therapeutic Target for Cancer Cells with Molecular Changes Associated with Activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK PathwaysClinical Cancer Research, 2012
- A Translational View of the Molecular Pathogenesis of Lung CancerJournal of Thoracic Oncology, 2007